Enzychem Lifescience Corp

Enzychem Lifesciences Corp, based in Englewood Cliffs, NJ, is at the forefront of developing novel small molecule therapeutics that address significant unmet medical needs in oncology and inflammatory diseases. Their flagship product, EC-18 Mosedipimod, is an oral small molecule derived from Sika deer antler, demonstrating activity across various therapeutic indications.

The company's proprietary EC-18 technology platform targets fundamental pathways in inflammation, with a pipeline that includes treatments for conditions such as chemoradiation-induced oral mucositis, chemotherapy-induced neutropenia, acute radiation syndrome, COVID-19, and non-alcoholic steatohepatitis. With over two decades of research backing their innovations, Enzychem is committed to improving the lives of patients facing serious health challenges.

Generated from the website